深圳奥派森生物电磁科技有限公司成立于2020年5月27日，是由前伊顿研究院郑庆杰博士创办，是一家从事基于电力电子和高频电磁场治疗肿瘤设备开发和技术服务的企业，公司具有独立的电气、细胞和动物实验室，公司研发的新型方波电场体外无创肿瘤治疗仪可以有效抑制恶性肿瘤的增殖（扩大）过程和肿瘤手术后的复发问题。
奥派森自2020年9月公司正式运营以来，多位电气、电磁场、医学博士和教授加盟助力公司科研进展，已于2020年底完成第一代TTF（Tumor Treating Fields）肿瘤电场治疗设备开发，并与多所高等院校和医院合作进行细胞实验和动物实验等生物实验验证设备的有效性和安全性。截至2023年底已完成脑胶质瘤、非小细胞肺癌、胰腺癌等癌种的细胞级实验验证和动物实验验证，细胞和动物实验结果表明抑制效果明显，符合行业已发表文献规律并具有更高的抑制效率。奥派森的TTF设备与PD1连用在非小细胞肺癌的细胞和动物实验上也取得了惊人的肿瘤抑制效果。
同时奥派森的TTF肿瘤电场治疗仪和电极产品设计迭代发展到第四代，相对市场已有TTF肿瘤电场治疗仪基于高频逆变器的技术方案具有更高的能量转化效率、静音无风扇设计方案、四倍的工作时间、智能的远程医患交互系统和人机操控界面， 截至2023年12月已完成型式试验报告。并与多家免疫药物公司、医院和科研院校联合申请了IIT（研究者发起临床试验）项目。目前奥派森已取得多项技术专利，还有多项专利正在申请之中，在肿瘤电场治疗上具有完全独立自主的知识产权。
Shenzhen AllPassion Bioelectromagnetics Technology Co., Ltd. is founded on May 27, 2020,it is founded by Dr. Zheng Qingjie of the former Eaton Research Institute, which is an enterprise engaged in the development and technical services of tumor treating equipment based on power electronics and high-frequency electromagnetic fields.
Since the company's official operation in September 2020, a number of electrical, electromagnetic field, medical doctors and professors have joined to help the company's scientific research progress, and has completed the development of the first generation of TTF (Tumor Treating Fields) tumor treating field therapy equipment at the end of 2020, and has cooperated with many universities and hospitals to conduct cell experiments and animal experiments and other biological experiments to verify the effectiveness and safety of the equipment. By the end of 2023, cell-level experimental verification and animal experimental verification of Glioma, Non-small cell lung cancer, Pancreatic cancer and other cancer types have been completed, and the results of cell and animal experiments have shown obvious inhibition effect, which is in line with the laws of published literature in the industry and has higher inhibition efficiency. AllPassion's TTF device and PD1 have also achieved amazing tumor suppression effects in cell and animal experiments on non-small cell lung cancer.
At the same time, the design iteration of the TTF tumor field therapy device and electrode product has been developed to the fourth generation, compared with the existing TTF tumor field therapy device based on high-frequency inverter technology on the market, it has higher energy conversion efficiency, silent fanless design scheme, four times the working time, intelligent remote doctor-patient interaction system and human-machine control interface, and the type test report has been completed as of December 2023. It has also jointly applied for IIT (Investigator-Initiated Clinical Trial) projects with a number of immunological drug companies, hospitals and scientific research institutions. At present, AllPassion has obtained a number of technical patents, and a number of patents are being applied, and has completely independent intellectual property rights in tumor treating treating tumors.
